RUNX1 inhibition combined with anti-vascular endothelial growth factor (anti-VEGF) therapy achieves better control of experimental choroidal neovascularization activity compared to monotherapy.
No, not yet, but our knowledge of the human genome sequence has enabled the development of other gene-based therapeutic approaches. Because we inherit one set of 23 chromosomes from each of our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback